Use of nonvolume-reduced (unmanipulated after thawing) umbilical cord blood stem cells for allogeneic transplantation results in safe engraftment

Theresa Hahn(Roswell Park Comprehensive Cancer Center), Phillip McCarthy(Roswell Park Comprehensive Cancer Center), Arvinder Bir(Roswell Park Comprehensive Cancer Center), Meir Wetzler, Maria R. Baer(University of Maryland, Baltimore), Udomsak Bunworasate(Chulalongkorn University), Wichai Chinratanalab(VA Tennessee Valley Healthcare System), Arif Alam(Roswell Park Comprehensive Cancer Center), B Bambach(Women & Children's Hospital of Buffalo), Joanne Becker(Roswell Park Comprehensive Cancer Center), James L. Slack(Memorial Sloan Kettering Cancer Center), Marina George(Roswell Park Comprehensive Cancer Center)
Bone Marrow Transplantation
July 1, 2003
10.1038/sj.bmt.1704091
Cited by 32

Related Papers

Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
|The Lancet Oncology|2017|493